1 / 67

Stewardship in the Setting of Multidrug-Resistant Gram-Negative Organisms

Stewardship in the Setting of Multidrug-Resistant Gram-Negative Organisms. Pranita D. Tamma, M.D., M.H.S Johns Hopkins University School of Medicine Associate Professor, Pediatrics. Disclosures. I have received a research grant from Merck, unrelated to this topic.

hoseam
Télécharger la présentation

Stewardship in the Setting of Multidrug-Resistant Gram-Negative Organisms

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stewardship in the Setting of Multidrug-Resistant Gram-Negative Organisms Pranita D. Tamma, M.D., M.H.S Johns Hopkins University School of Medicine Associate Professor, Pediatrics

  2. Disclosures • I have received a research grant from Merck, unrelated to this topic. • I have no conflicts of interest

  3. Objectives • Explain mechanisms of carbapenem resistance • Discuss the role of novel β-lactams in the treatment of carbapenem resistant gram-negative organisms • Review approaches to reporting carbapenem-resistant organisms to clinicians

  4. How Did We Get Here? • Bacterial resistance is not a new phenomenon • Multidrug resistance has been found in bacteria from environments separated from human activity for millions of years • For decades resistance profiles of gram-negative organisms were relatively stable • Bacterial resistance accelerated with antibiotic overuse Lechuguilla Cave, New Mexico Bhullar, et al. Plos One. 2012;7:e34953.

  5. Urgent Threats: Centers for Disease Control and Prevention Clostridiodes difficile Carbapenem-resistant Enterobacteriaceae Neisseria gonorrhoeae

  6. Mechanisms of Carbapenem Resistance Zowawi HM, et al. Nat Rev Urol2015;12:570-84.

  7. Carbapenemases *Because mobile genetic elements carrying carbapenemase genes may also carry ESBL genes (Class A) and/or AmpC encoding-genes (Class C), anticipated antibiotic susceptibility profiles for β-lactams may appear inconsistent

  8. Does Knowing if CRE are Carbapenemase Producing Matter? • Prognosis • The odds of dying within 14 days are more than 4 times greater for CP-CRE compared with non-CP-CRE bacteremicpatients • Spread to other patients • Dissemination between organisms and patients more likely with carbapenemase vs. non-carbapenemase producing organisms • Treatment decisions • Antibiotic selection varies by type of carbapenemase Tamma PD, et al. ClinInfect Dis. 2017;64:257-264.

  9. Pranita D. Tamma, Patricia J. Simner

  10. US FDA Approved Drugs

  11. Aztreonam/Avibactam

  12. Aztreonam NDMs, VIMs, IMPs

  13. Avibactam Aztreonam ESBLs, AmpCs, KPCs, OXA-48-like NDMs, VIMs, IMPs

  14. Activity of Aztreonam/Avibactam Against CRE * In vitro data suggest aztreonam/avibactam is also effective against isolates simultaneously producing both serine and MBL carbapenemases Sader H, et al. Antimicrob Ag Chemother 2018;62:e01856-17.

  15. What About P. aeruginosa in General? Susceptible defined as MICs ≤8 mcg/mL for Enterobacteriaceae and MICs ≤4 mcg/mL for Pseudomonas spp. and Acinetobacter spp. Karlowsky JA, et al. Antimicrob Agents Chemother 2017;61:e00427-17.

  16. Clinical Data ClinicalTrials.gov Identifiers: NCT02655419, NCT03329092 & NCT03580044

  17. Activity of Aztreonam/Avibactam Against MDRGNs Green represents susceptibility anticipated to be >90%, yellow represents susceptibility anticipated to be 30%-90%; red represents intrinsic resistance or susceptibility anticipated to be <30%

  18. Aztreonam/Avibactam

  19. Cefiderocol

  20. Siderophores • Cefiderocol is an injectable siderophore cephalosporin • Innate immune system minimizes available free iron in response to bacterial infections • Most iron is bound to hemoglobin, myoglobin, or the iron binding proteins • Bacterial infections cause upregulation in the production of siderophores • Siderophores are iron-chelating compounds that scavenge for free iron TillotsonGS. Infect Dis (Auckl) 2016;9:45-52. Ito A, et al. Antimicrob Agents Chemother 2016;60:7396-401.

  21. Cefiderocol • “Trojan Horse” approach to gain entry into bacteria • Once across the outer membrane it dissociates from the iron molecule and binds to penicillin binding proteins, disrupting cell wall synthesis • Circumvents common resistance mechanisms • Deficiencies in porin expression, upregulation of efflux pumps, serine or metallo-β-lactamases are not expected to cause frank resistance to cefiderocol TillotsonGS. Infect Dis (Auckl) 2016;9:45-52. Ito A, et al. Antimicrob Agents Chemother 2016;60:7396-401.

  22. KPC-Producing Enterobacteriaceae 127 international clinical isolates tested Dobias J, et al. Eur J ClinMicrobiol Infect Dis 2017; 36:2319-2327.

  23. Metallo-β-lactamase-Producing Enterobacteriaceae 134 international clinical isolates tested Dobias J, et al. Eur J ClinMicrobiol Infect Dis 2017; 36:2319-2327.

  24. OXA-48-like Producing Enterobacteriaceae 154 international clinical isolates tested Dobias J, et al. Eur J ClinMicrobiol Infect Dis 2017; 36:2319-2327.

  25. Carbapenemase-Producing P. aeruginosa 30 international clinical isolates tested Dobias J, et al. Eur J ClinMicrobiol Infect Dis 2017; 36:2319-2327.

  26. Carbapenemase-Producing A. baumannii 85 international clinical isolates tested Dobias J, et al. Eur J ClinMicrobiol Infect Dis 2017; 36:2319-2327.

  27. Activity of Cefiderocol Against MDRGNs Green represents susceptibility anticipated to be >90%, yellow represents susceptibility anticipated to be 30%-90%; red represents intrinsic resistance or susceptibility anticipated to be <30%

  28. MB-1: A Cautionary Tale

  29. MB-1: A Cautionary Tale • MIC50 & MIC90 assays conducted • Mutations in iron transporter gene piuAoccured relatively infrequently • Frequency of 8*10-7 at 4x MIC; none at 8x MIC Tomaras AP, et al. Antimicrob Agents Chemother 2013; 57:4197-4207.

  30. MB-1: A Cautionary Tale Control • Variable efficacy of MB-1 against P. aeruginosa clinical isolates • Lack of correlation between in vitro MB-1 MICs and the corresponding level of MB-1 efficacy in vivo • Hypothesis: Increases in endogenously produced P. aeruginosasiderophores downregulate other siderophore receptors, including those used by MB-1 Change Log10CFU after 24 hours MB-1 Isolates Neutropenic thigh model Tomaras AP, et al. Antimicrob Agents Chemother 2013; 57:4197-4207.

  31. MB-1: A Cautionary Tale Control • Variable efficacy of MB-1 against P. aeruginosa clinical isolates • Lack of correlation between in vitro MB-1 MICs and the corresponding level of MB-1 efficacy in vivo • Hypothesis: Increases in endogenously produced P. aeruginosasiderophores downregulate other siderophore receptors, including those used by MB-1 Cefiderocol structurally differs from MB-1 and potent activity has been observed in cefiderocol murine thigh models. But, we still need to remain vigilant! Change Log10CFU after 24 hours MB-1 Isolates Neutropenic thigh model Tomaras AP, et al. Antimicrob Agents Chemother 2013; 57(9):4197-4207.

  32. Potsmouth S, et al. Lancet Infect Dis 2018; 18:1319-1328. ClinicalTrials.gov Identifiers NCT02321800, NCT02714595, & NCT03032380

  33. Cefiderocol

  34. Ceftazidime/Avibactam

  35. Spectrum of Activity • Active against KPC and OXA-48-like producers • Can consider combining with aztreonam for coverage against metallo-β-lactamases • Ceftazidime-avibactam active against 62-88% of meropenem-nonsusceptibleP. aeruginosa • In a cohort of mostly carbapenem-resistant P. aeruginosa, 62% were susceptible to ceftazidime/avibactam whereas 73% were susceptible to ceftolozane/tazobactam Castanheira M, et al. Antimicrob Ag Chemother 2015; 59:3509-17. Sader HS, et al. Antimicrob Ag Chemother 2017;61. Sader HS, et al. DiagnMicrobiol Infect Dis. 2015; 83:389-94.

  36. Emergence of Resistance • Resistance observed during exposure to ceftazidime/avibactam therapy • Most frequently because of an amino acid substitution within or proximal to the omega loop of the KPC enzyme • Emergence of resistance on ceftazidime/avibactam may occur approximately 10% of the time • Mutations conferring resistance to ceftazidime/avibactam may reduce the potency of KPC-2 & KPC-3 enzymes, restoring susceptibility to carbapenems Humphries RM, et al. Antimicrob Ag Chemo 2015;59:6605-7. Humphries RM, et al. Antimicrob Ag Chemo 2017; 61:e00537. Shields R, et al. Clin Infect Dis 2016; 63: 1615-1618. Shields R, et al. Open Forum Infect Dis 2017; 4:ofx101. Gaibani P, et al. J AntimicrobChemother 2018;73:1525-9. Giddins ML, et al. Antimicrob Ag Chemother 2018; 62:e02101-17. Castanheira M, et al. mSphere 2018;3: e00408-18.

  37. Patient One Shields RK, et al. Antimicrob Agents Chemother 2017;61:02097-16

  38. Patient Two Shields RK, et al. Antimicrob Agents Chemother 2017;61:02097-16

  39. Patient Three Shields RK, et al. Antimicrob Agents Chemother 2017;61:02097-16

  40. Patient Three Unfortunately, available data suggest this restored carbapenem activity is generally not sustainable so clinical significance is unclear. Shields RK, et al. Antimicrob Agents Chemother 2017;61:02097-16

  41. Activity of Ceftazidime/Avibactam Against MDRGNs Green represents susceptibility anticipated to be >90%, yellow represents susceptibility anticipated to be 30%-90%; red represents intrinsic resistance or susceptibility anticipated to be <30%

  42. Ceftazidime-Avibactam

  43. Ceftolozane/Tazobactam

  44. Spectrum of Activity • Broadest P. aeruginosa activity compared with other commercially available β-lactams • Large cohort of carbapenem-resistant P. aeruginosa isolates from US and Europe, ceftolozane-tazobactam was susceptible against 78% • More active against US compared with European P. aeruginosa isolates • ~90% vs. 50% • Activity against P. aeruginosa displaying a mucoid phenotype is less reliable • Activity against extensively drug-resistant P. aeruginosa isolates from cystic fibrosis patients varies between 30-54% of isolates • Resistance generally due to de novo mutations impacting AmpC expression Farrell DJ, et al. Int J AntimicrobAgents 2014;43:533-9. Sader HS, et al. J AntimicrobChemother 2014; 69:2713-22. Wi YM, et al. Antimicrob Ag Chemother 2018; 62: e01970-17. Forrester JB, et al. Open Forum Infect Dis 2018; 5:ofy158. Kuti JL, et al. DiagnMicrobiol Infect Dis 2015; 83:53-5. Grohs P, et al. Antimicrob Ag Chemother 2017;61. e00766-17.

  45. Activity of Ceftolozane/Tazobactam Against MDRGNs Green represents susceptibility anticipated to be >90%, yellow represents susceptibility anticipated to be 30%-90%; red represents intrinsic resistance or susceptibility anticipated to be <30%

  46. Ceftolozane/Tazobactam

  47. Imipenem-cilastatin/Relebactam

  48. Available data indicate its activity against OXA-48-like carbapenemases is poor LapueblaA, et al. Antimicrob Ag Chemother 2015; 59:5029-5031.

  49. PHASE II Study: cUTIs Adults with cUTIs or pyelonephritis Could convert to ciprofloxacin after 4 days; total duration 4-14 days Imipenem 500/ relebactam 250 mg IV q6h (n=74) Imipenem 500/ relebactam 125 mg IV q6h (n=82) Imipenem 500 mg IV q6h (n=81) Clinical response at discontinuation of IV therapy 97% 99% 99% ClinicalTrials.gov Identifier: NCT01505634

  50. PHASE II Study: cIAIs Total duration of therapy 4-14 days Adults with cIAIs 34 patients with imipenem-nonsusceptible infections with good response Imipenem 500/ relebactam 250 mg IV q6h (n=89) Imipenem 500/ relebactam 125 mg IV q6h (n=96) Imipenem 500 mg IV q6h (n=92) Clinical response at discontinuation of IV therapy 96% 99% 95% ClinicalTrials.gov Identifier: NCT01505634

More Related